Italia markets closed

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
43,40+0,22 (+0,51%)
Al 03:49PM EST. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente43,18
Aperto43,46
Denaro43,63 x 1200
Lettera43,74 x 1100
Min-Max giorno43,20 - 44,42
Intervallo di 52 settimane27,77 - 88,18
Volume400.253
Media Volume902.485
Capitalizzazione3,058B
Beta (5 anni mensile)1,66
Rapporto PE (ttm)N/D
EPS (ttm)-3,59
Prossima data utili27 feb 2023 - 03 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A80,08
  • GlobeNewswire

    Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease

    BEAM-101 BEACON Trial Represents the First Clinical Trial of a Base Editor in the United StatesCAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the first patient has been enrolled in the company’s BEACON trial. BEACON is an open-label, single-arm, multicenter, Phase 1/2 clinical trial designed to evaluate the safety and efficacy of BEAM-101 in adult

  • GlobeNewswire

    Beam Therapeutics to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following upcoming investor conferences: 2022 Jefferies London Healthcare Conference (fireside chat) on Tuesday, November 15, 2022, at 8:00 a.m. GMT; and,Evercore ISI Virtual HealthCONx Conference 2022 (fireside chat) on Thursday, December 1, 2022, at 8:50 a.m. ET. Li

  • GlobeNewswire

    Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results

    Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Strategy Execution IND-enabling Studies Underway for BEAM-301 for Treatment of GSDIa BEAM-302 Nominated as Development Candidate for Treatment of Alpha-1 Antitrypsin Deficiency; Targeting Durable Gene Correction Designed to Address Both Lung and Liver Disease New Data Highlighting Enhanced Conditioning Approach for Hematologic Transplant (ESCAPE) to be Presented at ASH Ended T